These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 37047616)
1. Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification. Sugeno N; Hasegawa T Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047616 [TBL] [Abstract][Full Text] [Related]
2. Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Guhathakurta S; Bok E; Evangelista BA; Kim YS Prog Neurobiol; 2017 Jul; 154():21-36. PubMed ID: 28445713 [TBL] [Abstract][Full Text] [Related]
3. DNA methylation in Parkinson's disease. Wüllner U; Kaut O; deBoni L; Piston D; Schmitt I J Neurochem; 2016 Oct; 139 Suppl 1():108-120. PubMed ID: 27120258 [TBL] [Abstract][Full Text] [Related]
4. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. Matsumoto L; Takuma H; Tamaoka A; Kurisaki H; Date H; Tsuji S; Iwata A PLoS One; 2010 Nov; 5(11):e15522. PubMed ID: 21124796 [TBL] [Abstract][Full Text] [Related]
5. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. Jowaed A; Schmitt I; Kaut O; Wüllner U J Neurosci; 2010 May; 30(18):6355-9. PubMed ID: 20445061 [TBL] [Abstract][Full Text] [Related]
6. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085 [TBL] [Abstract][Full Text] [Related]
7. Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. Voutsinas GE; Stavrou EF; Karousos G; Dasoula A; Papachatzopoulou A; Syrrou M; Verkerk AJ; van der Spek P; Patrinos GP; Stöger R; Athanassiadou A Hum Mutat; 2010 Jun; 31(6):685-91. PubMed ID: 20340137 [TBL] [Abstract][Full Text] [Related]
8. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein. Rutherford NJ; Moore BD; Golde TE; Giasson BI J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882 [TBL] [Abstract][Full Text] [Related]
9. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model. Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic approach to early-onset Parkinson's disease: low methylation status of SNCA and PARK2 promoter regions. Eryilmaz IE; Cecener G; Erer S; Egeli U; Tunca B; Zarifoglu M; Elibol B; Bora Tokcaer A; Saka E; Demirkiran M; Akbostanci C; Dogu O; Colakoglu B; Kenangil G; Kaleagasi H Neurol Res; 2017 Nov; 39(11):965-972. PubMed ID: 28830306 [TBL] [Abstract][Full Text] [Related]
11. Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson's disease. Guhathakurta S; Evangelista BA; Ghosh S; Basu S; Kim YS Mol Brain; 2017 Feb; 10(1):6. PubMed ID: 28173842 [TBL] [Abstract][Full Text] [Related]